Slovakia

Reimbursed Care Access

Slovakia maintains a restrictive statutory regime for classic psychedelic compounds: most serotonergic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X, ibogaine, ayahuasca) are controlled under the national narcotics statute with no authorised outpatient medical program outside clinical research. Separately, esketamine (Spravato) holds an EU marketing authorisation but — after national health-technology assessment — has not been fully accepted onto Slovakia's public reimbursement lists; ketamine remains an authorised and routinely used anaesthetic (and is used off‑label in private/academic settings for psychiatric indications), but such off‑label psychiatric uses are generally not covered by public insurance and are delivered out‑of‑pocket or within research.